AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC decreased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.1% during the 4th quarter, HoldingsChannel reports. The fund owned 43,428 shares of the company’s stock after selling 1,377 shares during the quarter. Snowden Capital Advisors LLC’s holdings in AstraZeneca were worth $2,845,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Banque Transatlantique SA acquired a new position in shares of AstraZeneca during the 4th quarter valued at about $26,000. Albion Financial Group UT boosted its position in shares of AstraZeneca by 68.9% during the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after acquiring an additional 248 shares during the last quarter. CoreCap Advisors LLC boosted its position in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock valued at $42,000 after acquiring an additional 155 shares during the last quarter. Crews Bank & Trust acquired a new position in shares of AstraZeneca during the 4th quarter valued at about $55,000. Finally, Golden State Wealth Management LLC acquired a new position in shares of AstraZeneca during the 4th quarter valued at about $55,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the topic of several recent research reports. Morgan Stanley initiated coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They set an “overweight” rating on the stock. UBS Group raised shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. Finally, BNP Paribas initiated coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price on the stock. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca has an average rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Trading Up 1.3%

NASDAQ AZN opened at $68.81 on Friday. The firm’s 50-day moving average is $70.46 and its two-hundred day moving average is $69.47. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. The stock has a market capitalization of $213.40 billion, a P/E ratio of 30.45, a PEG ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to analysts’ expectations of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.06 earnings per share. On average, sell-side analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.